We are live on ! Find out more
Royal Bank of Canada

Royal Bank of Canada Portfolio holdings

AUM $570B
1-Year Est. Return 27.57%
 

Royal Bank of Canada (RBC), founded in 1864 and headquartered in Toronto, is Canada’s largest bank by market capitalization and one of the leading financial institutions in North America, offering a comprehensive suite of services including personal and commercial banking, wealth management, insurance, and capital markets. Managing hundreds of billions in assets, RBC serves millions of clients globally, with a significant presence in the U.S. and Caribbean through subsidiaries like RBC Wealth Management and City National Bank. Known for its stability and consistent profitability, RBC has earned a reputation as a conservative yet innovative bank, expanding its digital offerings and sustainability initiatives in recent years. With a strong focus on customer service and a robust international footprint, RBC remains a cornerstone of the Canadian and global financial systems.

This Fund
S&P 500
This Quarter Est. Return
+4.82%
1 Year Est. Return
+27.57%
3 Year Est. Return
+75.99%
5 Year Est. Return
+94.97%
10 Year Est. Return
+325.25%
AUM
$228B
AUM Growth
+$19.5B
Cap. Flow
+$9.66B
Cap. Flow %
4.24%
Top 10 Hldgs %
19.68%
Holding
7,447
New
331
Increased
2,461
Reduced
3,156
Closed
486

Sector Composition

Rank Sector Weight
1 Financials 21.58%
2 Energy 8.65%
3 Industrials 8.54%
4 Technology 7.61%
5 Communication Services 7.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TIMB icon
6101
TIM SA
TIMB
$8.27B
$3K ﹤0.01%
143
-2,100
-94% -$38.9K
TRIB
6102
Trinity Biotech
TRIB
$8.01M
$3K ﹤0.01%
4
TVTX icon
6103
Travere Therapeutics
TVTX
$5.79B
$3K ﹤0.01%
140
-3,278
-96% -$74.9K
UIS icon
6104
Unisys
UIS
$210M
$3K ﹤0.01%
335
-4,278
-93% -$35.1K
VSA
6105
VisionSys AI
VSA
$10.3M
0
BCOV
6106
DELISTED
Brightcove, Inc.
BCOV
$3K ﹤0.01%
425
-3,071
-88% -$22.3K
VIRX
6107
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3K ﹤0.01%
+24
New +$2.25K
HAYN
6108
DELISTED
Haynes International, Inc.
HAYN
$3K ﹤0.01%
100
-1,510
-94% -$51.4K
ITI
6109
DELISTED
Iteris, Inc.
ITI
$3K ﹤0.01%
487
-2,000
-80% -$13.6K
TELL
6110
DELISTED
Tellurian Inc.
TELL
$3K ﹤0.01%
304
-4,277
-93% -$45.8K
GTHX
6111
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3K ﹤0.01%
161
-480
-75% -$10.3K
KA
6112
DELISTED
Kineta, Inc. Common Stock
KA
$3K ﹤0.01%
+4
New +$1.53K
PRTK
6113
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3K ﹤0.01%
166
-1,899
-92% -$39.6K
MGI
6114
DELISTED
MoneyGram International, Inc. New
MGI
$3K ﹤0.01%
196
-2,678
-93% -$39.1K
OPNT
6115
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$3K ﹤0.01%
145
-55
-28% -$1.76K
NH
6116
DELISTED
NantHealth, Inc
NH
$3K ﹤0.01%
66
-52
-44% -$2.76K
CALA
6117
DELISTED
Calithera Biosciences, Inc
CALA
$3K ﹤0.01%
16
-142
-90% -$36.4K
ZIXI
6118
DELISTED
Zix Corporation
ZIXI
$3K ﹤0.01%
778
-4,511
-85% -$21.2K
MSON
6119
DELISTED
Misonix Inc
MSON
$3K ﹤0.01%
301
+300
+30,000% +$3.02K
GSUM
6120
DELISTED
Gridsum Holding Inc.
GSUM
$3K ﹤0.01%
+300
New +$2.67K
TNAV
6121
DELISTED
Telenav Inc.
TNAV
$3K ﹤0.01%
583
-2,944
-83% -$16.4K
ACHN
6122
DELISTED
Achillion Pharmaceuticals
ACHN
$3K ﹤0.01%
894
-10,862
-92% -$39.5K
BOLD
6123
DELISTED
Audentes Therapeutics, Inc
BOLD
$3K ﹤0.01%
69
-1,350
-95% -$37.1K
TRCB
6124
DELISTED
Two River Bancorp
TRCB
$3K ﹤0.01%
146
-455
-76% -$8.55K
MB
6125
DELISTED
MINDBODY, Inc. Class A Common Stock
MB
$3K ﹤0.01%
111
-3,510
-97% -$108K

Similar funds

Royal Bank of Canada's Q4 2017 Portfolio in Review

As of Q4 2017, Royal Bank of Canada held 7,447 positions worth $228B, up 9.4% from $208B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Royal Bank of Canada deployed $9.66B of net new capital in Q4 2017, opening 331 new positions and adding to 2,461 existing holdings. Its largest new stake was Maxar Technologies Inc. Common Stock: 2,562,561 shares worth $165M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 22% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was iShares Core S&P 500 ETF, an estimated $611M trimmed.

  • Royal Bank of Canada's largest Q4 2017 buy was Maxar Technologies Inc. Common Stock: 2,562,561 shares worth $165M.
  • Royal Bank of Canada added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $2.31B increase.
  • Royal Bank of Canada's biggest Q4 2017 reduction was iShares Core S&P 500 ETF, cutting an estimated $611M.
  • Royal Bank of Canada fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $144M.
  • Royal Bank of Canada's ten largest holdings make up 20% of its $228B portfolio in Q4 2017.
  • Royal Bank of Canada opened 331 new positions and closed 486 in Q4 2017.
  • Royal Bank of Canada's portfolio value rose 9.4% quarter-over-quarter to $228B.

Based on Royal Bank of Canada's 13F filing for Q4 2017, filed 14 Feb 2018.